Merk and Moderna's mRNA Cancer Vaccine Shows Promising Results
A new personalized mRNA vaccine has shown promising results in preventing melanoma recurrence, according to a recent trial from Merck and Moderna.
The study, which involved over 1,100 people who had melanoma removed by surgery, found that the combination of the mRNA vaccine with Keytruda, an immunotherapy medication, significantly improved recurrence-free survival rates compared to using Keytruda alone.
Dr. John Cooke, director of the Center for RNA Therapeutics at Houston Methodist, described the results as an 'exciting breakthrough' in fighting cancer and noted that mRNA vaccines can be effective against not only viruses but also cancer.
The trial's success has sparked hopes that mRNA-based therapies could become a new weapon in the fight against cancer, with researchers exploring its potential use for other types of tumors, including bladder cancer and lung cancer.